Sökning: "anticancer drug"
Visar resultat 1 - 5 av 110 avhandlingar innehållade orden anticancer drug.
1. Circumventing drug resistance : Studies exploring the expediency of a total cell kill chemoresistance assay
Sammanfattning : Cellular resistance to anti-cancer drugs is considered to be the major cause of treatment failure in clinical practice. The present studies have therefore focused on ways to circumvent resistance as evaluated by an in vitro chemoresistance assay. LÄS MER
2. Translational Tumor Drug Delivery : Doxorubicin formulation performance, intracellular uptake and molecular diffusion
Sammanfattning : Globally, hepatocellular carcinoma (HCC) is the most common form of liver cancer and a leading cause of cancer death. One important risk factor is liver cirrhosis and the disease progression is characterized by deposition of extracellular matrix proteins that form a fibrous network, which increases liver stiffness and may limit the effectiveness of different treatment strategies. LÄS MER
3. Integrating Efficacy and Toxicity in Preclinical Anticancer Drug Development : Methods and Applications
Sammanfattning : Preclinical testing is an important part of cancer drug development. The aim of this thesis was to establish and evaluate preclinical in vitro methods useful in the development of new anticancer drugs. In paper I, the development of non-clonogenic assays (FMCA-GM) using CD34+ stem cells for assessment of haematological toxicity was described. LÄS MER
4. Copper-transporting proteins and their interactions with platinum-based anticancer substances
Sammanfattning : Cisplatin (CisPt) is an important drug that is used against various cancers, including testicular, ovarian, lung, head, and neck cancer. However, its effects are limited by cellular resistance. LÄS MER
5. Chemical transformation of the anticancer drug oxaliplatin
Sammanfattning : Oxaliplatin is a new platinum based cytostatic drug. It is used in combination with 5-fluorouracil and leucovorin, both as palliative and adjuvant treatment of metastatic colorectal cancer. Various biotransformation products are formed non-enzymatically after oxaliplatin administration. LÄS MER